For all press and media enquiries please contact mediarelations@chiesi.com
Chiesi is the only European pharmaceutical company and the first Italian company ever to be included in the World’s Best Workplaces™ The accolade reflects Chiesi's dedication to people’s well-being, continuous improvement, and creating a positive work environment Chiesi was also recently ranked in…
Chiesi Group is making a strategic investment of €400 to establish its new Biotech Center of Excellence in Parma. The Center is designed to integrate the entire supply chain, enhancing innovation and production, while its seamless research-production integration will accelerate product development…
At the 2024 European Respiratory Society Congress (ERS), Chiesi Group will convene two symposia to highlight the importance of patient centricity in managing asthma and COPD Chiesi Group will present the value for patients in using innovative decentralized elements in clinical trial design, with…
Chiesi Group's Sustainability Report 2023 highlights impacts on strategic areas such as Patients, Planet, People and Prosperity while anticipating regulatory changes. Patients: Chiesi invested 23.8% of its revenues in research and development and advocated for patients with respiratory conditions,…
Design of multi-center study is based on previous Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD) OHB-607 has the potential to be the first innovative respiratory therapeutic advance for extremely preterm neonates in over thirty years. Oak…
The collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts Parma, 14 May 2024 – Chiesi Group, a research-oriented international biopharmaceutical group, proudly announces the signing of a…
Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales…
Highlights from Chiesi Group’s 2023 financial report: Sales increased to over €3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions 24% of 2023 sales were devoted to R&D to create innovative…
Chiesi Group announces a major step in the development of carbon minimal inhalers with the initiation of a new phase III long-term safety trial. The trial comes after the completion of two short-term clinical safety studies with the new low global warming potential propellant and three clinical…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
